Literature DB >> 10833408

Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells.

K W Zhao1, E F Neufeld.   

Abstract

alpha-N-Acetylglucosaminidase (EC 3.2.1.50) is a lysosomal enzyme that is deficient in the genetic disorder Sanfilippo syndrome type B. To study the human enzyme, we expressed its cDNA in Lec1 mutant Chinese hamster ovary (CHO) cells, which do not synthesize complex oligosaccharides. The enzyme was purified to apparent homogeneity from culture medium by chromatography on concanavalin A-Sepharose, Poros 20-heparin, and aminooctyl-agarose. The purified enzyme migrated as a single band of 83 kDa on SDS-PAGE and as two peaks corresponding to monomeric and dimeric forms on Sephacryl-300. It had an apparent K(m) of 0.22 mM toward 4-methylumbelliferyl-alpha-N-acetylglucosaminide and was competitively inhibited by two potential transition analogs, 2-acetamido-1,2-dideoxynojirimycin (K(i) = 0.45 microM) and 6-acetamido-6-deoxycastanospermine (K(i) = 0.087 microM). Activity was also inhibited by mercurials but not by N-ethylmaleimide or iodoacetamide, suggesting the presence of essential sulfhydryl residues that are buried. The purified enzyme preparation corrected the abnormal [(35)S]glycosaminoglycan catabolism of Sanfilippo B fibroblasts in a mannose 6-phosphate-inhibitable manner, but its effectiveness was surprisingly low. Metabolic labeling experiments showed that the recombinant alpha-N-acetylglucosaminidase secreted by CHO cells had only a trace of mannose 6-phosphate, probably derived from contaminating endogenous CHO enzyme. This contrasts with the presence of mannose 6-phosphate on naturally occurring alpha-N-acetylglucosaminidase secreted by diploid human fibroblasts and on recombinant human alpha-l-iduronidase secreted by the same CHO cells. Thus contrary to current belief, overexpressing CHO cells do not necessarily secrete recombinant lysosomal enzyme with the mannose 6-phosphate-targeting signal; this finding has implications for the preparation of such enzymes for therapeutic purposes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833408     DOI: 10.1006/prep.2000.1230

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  26 in total

1.  Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB).

Authors:  C E Beesley; M Jackson; E P Young; A Vellodi; B G Winchester
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.

Authors:  Wenyong Tong; Chrissa A Dwyer; Bryan E Thacker; Charles A Glass; Jillian R Brown; Kristina Hamill; Kelley W Moremen; Stéphane Sarrazin; Philip L S M Gordts; Lara E Dozier; Gentry N Patrick; Yitzhak Tor; Jeffrey D Esko
Journal:  Mol Ther       Date:  2017-08-12       Impact factor: 11.454

3.  Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.

Authors:  Shih-Hsin Kan; Mika Aoyagi-Scharber; Steven Q Le; Jon Vincelette; Kazuhiro Ohmi; Sherry Bullens; Daniel J Wendt; Terri M Christianson; Pascale M N Tiger; Jillian R Brown; Roger Lawrence; Bryan K Yip; John Holtzinger; Anil Bagri; Danielle Crippen-Harmon; Kristen N Vondrak; Zhi Chen; Chuck M Hague; Josh C Woloszynek; Diana S Cheung; Katherine A Webster; Evan G Adintori; Melanie J Lo; Wesley Wong; Paul A Fitzpatrick; Jonathan H LeBowitz; Brett E Crawford; Stuart Bunting; Patricia I Dickson; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 4.  New strategies for enzyme replacement therapy for lysosomal storage diseases.

Authors:  Jeffrey H Grubb; Carole Vogler; William S Sly
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

Review 5.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

6.  Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.

Authors:  Yunxiang Zhu; Xuemei Li; Alison McVie-Wylie; Canwen Jiang; Beth L Thurberg; Nina Raben; Robert J Mattaliano; Seng H Cheng
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

7.  High-Throughput Screen Fails to Identify Compounds That Enhance Residual Enzyme Activity of Mutant N-Acetyl-α-Glucosaminidase in Mucopolysaccharidosis Type IIIB.

Authors:  O L M Meijer; P van den Biggelaar; R Ofman; F A Wijburg; N van Vlies
Journal:  JIMD Rep       Date:  2017-08-24

8.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.

Authors:  Jonathan H LeBowitz; Jeffrey H Grubb; John A Maga; Deborah H Schmiel; Carole Vogler; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

9.  Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.

Authors:  Michael B Tropak; Stephen P Reid; Marianne Guiral; Stephen G Withers; Don Mahuran
Journal:  J Biol Chem       Date:  2004-01-14       Impact factor: 5.157

10.  Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB.

Authors:  Elizabeth Ficko-Blean; Keith A Stubbs; Oksana Nemirovsky; David J Vocadlo; Alisdair B Boraston
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.